Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02915744
Registration number
NCT02915744
Ethics application status
Date submitted
22/09/2016
Date registered
27/09/2016
Date last updated
14/04/2023
Titles & IDs
Public title
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Query!
Scientific title
A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
Query!
Secondary ID [1]
0
0
15-102-14
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ATTAIN
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastasis
0
0
Query!
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Cancer
0
0
0
0
Query!
Brain
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - NKTR-102
Treatment: Drugs - Eribulin
Treatment: Drugs - Ixabepilone
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Paclitaxel
Treatment: Drugs - Docetaxel
Treatment: Drugs - Nab-paclitaxel
Experimental: NKTR-102 - In Group A, NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle.
Active Comparator: Treatment of Physician's Choice (TPC) - In Group B, TPC will be administered per standard of care. Patients randomized to TPC will receive single-agent IV chemotherapy, limited to choice of one of the following 7 agents: eribulin, ixabepilone, vinorelbine, gemcitabine, paclitaxel, docetaxel, or nab-paclitaxel.
Treatment: Drugs: NKTR-102
Treatment: Drugs: Eribulin
Treatment: Drugs: Ixabepilone
Treatment: Drugs: Vinorelbine
Treatment: Drugs: Gemcitabine
Treatment: Drugs: Paclitaxel
Treatment: Drugs: Docetaxel
Treatment: Drugs: Nab-paclitaxel
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS) of Patients
Query!
Assessment method [1]
0
0
To compare Overall Survival (OS) of patients who receive 145 mg/m2 NKTR-102 given once every 21 days (q21d) with OS of patients who receive Treatment of Physician's Choice (TPC). Overall survival is defined as the time from the date of randomization to the date of death from any cause. Patients will be followed until their date of death or until final database closure. Patients who are lost-to-follow-up or are alive at the time of analysis will be censored at the time they were last known to be alive or at the date of event cut-off for OS analysis.
Query!
Timepoint [1]
0
0
Within 3 years from study start
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (Outside the Central Nervous System)
Query!
Assessment method [1]
0
0
Progression-Free Survival (PFS) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) or of death from any cause. The date of global deterioration or symptomatic deterioration will not be used as the date of PD. The assessment of PFS outside the CNS will utilize RECIST criteria v1.1.
Query!
Timepoint [1]
0
0
Through study completion, an expected average of 1 year
Query!
Secondary outcome [2]
0
0
Progression-Free Survival in Brain Metastasis (PFS-BM)
Query!
Assessment method [2]
0
0
Progression-Free Survival in Brain Metastasis (PFS-BM) is defined as the time from the date of randomization to the earliest evidence of documented Progressive Disease (PD) per Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) in brain metastases or death from any cause. The PD will also be determined by the investigator's assessments. Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression.
Query!
Timepoint [2]
0
0
Through study completion, an expected average of 1 year
Query!
Secondary outcome [3]
0
0
Progression-Free Survival (Overall)
Query!
Assessment method [3]
0
0
Progression-free survival (CNS and peripheral) is defined as the time from the date of randomization to the earliest evidence of documented PD in either the CNS or peripheral (using RANO-BM) or death from any cause. The PD will be determined by both the investigator's and the central imaging facility assessments. The same statistical methods that were used for PFS and PFS-BM will be used for PFS (Overall). Progressive Disease (PD) is defined as at least a 20% increase in the sum of longest diameters of CNS target lesions, taking as reference the smallest sum on study. This included the baseline sum if that was the smallest on study. In addition to the relative increase of 20%, at least 1 lesion had to increase by an absolute value of 5 mm or more to be considered progression.
Query!
Timepoint [3]
0
0
Through study completion, an expected average of 1 year
Query!
Secondary outcome [4]
0
0
Objective Response Rates (ORR) of the NKTR-102 Treatment and the Treatment of Physician's Choice (TPC)
Query!
Assessment method [4]
0
0
RECIST criteria for lesions outside the Central Nervous System (CNS); RANO-BM criteria for CNS lesions) based upon the best response as assessed by the central imaging facility. CR is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had to have reduction in short axis to < 10 mm. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. ORR is calculated as the sum of CR and PR. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Query!
Timepoint [4]
0
0
Through study completion, an expected average of 1 year
Query!
Secondary outcome [5]
0
0
Clinical Benefit Rate (CBR)
Query!
Assessment method [5]
0
0
Clinical Benefit Rate will be defined as the proportion of patients having a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) for at least 4 months (= 120 days). CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Query!
Timepoint [5]
0
0
For at least 4 months, with an expected average of 1 year
Query!
Secondary outcome [6]
0
0
Duration of Response (DoR)
Query!
Assessment method [6]
0
0
Duration of response (DoR) outside the CNS will be defined as the time from first documented CR or PR until the earliest evidence of disease progression per RECIST v1.1 or death from any cause. CR is defined as disappearance of all target lesions for at least 4 weeks with no new lesions, not use of corticosteroids, and patient was stable or improved clinically. PR is defined as at least a 30% decrease in the sum of longest diameters sustained for at least 4 weeks, no new lesions; stable to decreased corticosteroid dose; stable or improved clinically. Progressive Disease (PD) is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that was the smallest on study). Stable Disease (SD) is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Query!
Timepoint [6]
0
0
Through study completion, an expected average of 1 year
Query!
Secondary outcome [7]
0
0
Compare Health-Related Quality of Life (HRQoL) Using the European Organisation for Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30) Module With the Brain Neoplasms 20-question (BN-20) Subscale.
Query!
Assessment method [7]
0
0
The EORTC QLQ-BN20 Scale has a series of 20 questions each of which involve reporting a scale from 1-4. It is an increasing scale where a score of one indicates "not at all" while a score of four indicates "very much". The minimum score is 20 and the maximum score is 80. The higher the score the worse the outcome.
Query!
Timepoint [7]
0
0
Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44.
Query!
Secondary outcome [8]
0
0
Compare Health-Related Quality of Life (HRQoL) Using the the EuroQoL 5D (EQ-5D-5L™)
Query!
Assessment method [8]
0
0
The EQ-5D-5L scale is used to measure health by having a patient answer a series of questions. There are a series of 5 questions each of which is scaled from a score of 4-20 in increasing increments of 4. The scale is numbered from 0 to 100 where 100 means the beast health you can imagine and 0 means the worst health.
Query!
Timepoint [8]
0
0
Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44
Query!
Secondary outcome [9]
0
0
Compare Health-Related Quality of Life (HRQoL) Using the Brief Fatigue Inventory (BFI)
Query!
Assessment method [9]
0
0
The Brief Fatigue Inventory scale utilizes a series of 4 questions. The first three are scored with a scale from 1-10. The fourth question has 6 six sub components each of which are scored with a scale of 1-10. For every scale, a score of 0 indicates no fatigue/interference where a score of 10 indicates as bad as you can imagine. A patient's score can range from 0 to 100 where 0 indicates the best outcome and 100 indicates the worst.
Query!
Timepoint [9]
0
0
Baseline (prior to first dose of study treatment in Cycle 1 [cycle length = 21 for NKTR-102 or 28 days for TPC] and end of Cycle 44
Query!
Secondary outcome [10]
0
0
Magnitude of Clinical Benefit Assessed by ESMO-MCBS Derived From Overall Survival
Query!
Assessment method [10]
0
0
The magnitude of clinical benefit of NKTR-102 is assessed by the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) (v1.0). The scale is graded 5, 4, 3, 2, 1, where grades 5 and 4 represent a high level of proven clinical benefit, and grade 1 represents no clinical benefit. To determine the magnitude of clinical benefit when the median OS with the standard of treatment is = 1 year, the score is derived from the Hazard Ratio (HR) of Overall Survival, overall survival gain, and QoL improvement between two treatment arms. Values reported in the data table are Overall Survival values.
Query!
Timepoint [10]
0
0
Through study completion, within 3 years from study start
Query!
Secondary outcome [11]
0
0
Number of Participants With Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3
Query!
Assessment method [11]
0
0
The number of participants with adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.3
Query!
Timepoint [11]
0
0
Through study completion, an expected average of 1 year
Query!
Eligibility
Key inclusion criteria
- Female or male, age = 18 years.
- Histologically-confirmed carcinoma of the breast (either the primary or metastatic
lesions) for whom single-agent cytotoxic chemotherapy is indicated. Patients may have
either measurable or non-measurable disease according to RECIST version 1.1.
- Patients must have a history of brain metastases that are non-progressing.
- For triple-negative breast cancer, a minimum of 1 prior cytotoxic chemotherapy regimen
must have been administered for the indication of metastatic disease.Depending on
receptor status, 1 or 2 prior cytotoxic regimens are required prior to enrollment in
this trial; hormonal and/or human epidermal growth factor receptor 2 (HER2) -targeted
agents may be required.
- Have had prior therapy (administered in the neoadjuvant, adjuvant, and/or metastatic
setting) with an anthracycline, a taxane, and capecitabine (prior anthracycline can be
omitted if not medically appropriate or contraindicated for the patient).
- Last dose of anticancer therapy must have been administered within 6 months of the
date of randomization into this study.
- All anticancer- and radiation therapy-related toxicities must be completely resolved
or downgraded to Grade 1 or less (neuropathy may be Grade 2 or less).
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Demonstrate adequate organ function obtained within 14 days prior to randomization and
analyzed by the central laboratory.
- Women of childbearing potential (WCBP) must agree to use highly effective methods of
birth control throughout the duration of the study until 6 months following the last
dose of study drug.
- Males with female partners of child-bearing potential must agree to use a barrier
contraception (e.g., condom with spermicidal foam/gel/film/cream/suppository)
throughout the duration of the study until 6 months following the last dose of study
drug; in addition to their female partner using either an intrauterine device or
hormonal contraception and continuing until 6 months following the last dose of study
drug. Male patients should not donate sperm until 6 months following the last dose of
study drug.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Last dose of anticancer therapy (including HER2-targeted therapy) within 14 days prior
to randomization.
- High-dose chemotherapy followed by stem cell transplantation (autologous or
allogeneic).
- Major surgery within 28 days prior to randomization.
- Concomitant use of any anticancer therapy or use of any investigational agent(s).
- Received prior treatment for cancer with a camptothecin-derived agent.
- Lesions on imaging, by cerebrospinal fluid or with neurological findings that are
consistent with leptomeningeal disease or meningeal carcinomatosis.
- Chronic or acute GI disorders resulting in diarrhea of any severity grade.
- Patients who are pregnant or lactating, plan to get pregnant, or have a positive serum
pregnancy test prior to randomization.
- Enzyme-inducing anti-epileptic drugs (EIAEDs) within 14 days of randomization.
- Hepatitis B or C, tuberculosis, or HIV.
- Cirrhosis.
- Prior malignancy (other than breast cancer) unless diagnosed and definitively treated
more than 5 years prior to randomization.
- Daily use of oxygen supplementation.
- Significant known cardiovascular impairment.
- Prior treatment with NKTR-102.
- Psychiatric illness, social situation, or geographical situation that preclude
informed consent or limit compliance.
- Known intolerance or hypersensitivity to any of the products used in this study or
their excipients.
- For patients selecting vinorelbine or gemcitabine as the TPC agent, patients may not
receive yellow fever vaccine in the 28 days prior to randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2016
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
178
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Investigatory Site - Albury - Albury
Query!
Recruitment hospital [2]
0
0
Investigator Site - Darlinghurst - Darlinghurst
Query!
Recruitment hospital [3]
0
0
Investigator Site - Wollongong - Wollongong
Query!
Recruitment hospital [4]
0
0
Investigator Site - Subiaco - Subiaco
Query!
Recruitment hospital [5]
0
0
Investigator Site - Box Hill - Box Hill
Query!
Recruitment hospital [6]
0
0
Investigator Site - Nedlands - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2640 - Albury
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [4]
0
0
6008 - Subiaco
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Georgia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Maryland
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Massachusetts
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Minnesota
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New York
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
North Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Tennessee
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Texas
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Utah
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Washington
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Brussels
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Charleroi
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Edegem
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Liège
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Woluwe-Saint-Lambert
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Quebec
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Le Mans
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Nîmes
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Paris
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Rennes
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Rouen
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Strasbourg
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Beersheba
Query!
Country [29]
0
0
Israel
Query!
State/province [29]
0
0
Haifa
Query!
Country [30]
0
0
Israel
Query!
State/province [30]
0
0
Tel Aviv
Query!
Country [31]
0
0
Italy
Query!
State/province [31]
0
0
Milano
Query!
Country [32]
0
0
Italy
Query!
State/province [32]
0
0
Milan
Query!
Country [33]
0
0
Italy
Query!
State/province [33]
0
0
Napoli
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Roma
Query!
Country [35]
0
0
Portugal
Query!
State/province [35]
0
0
Lisboa
Query!
Country [36]
0
0
Portugal
Query!
State/province [36]
0
0
Porto
Query!
Country [37]
0
0
Spain
Query!
State/province [37]
0
0
Barcelona
Query!
Country [38]
0
0
Spain
Query!
State/province [38]
0
0
Madrid
Query!
Country [39]
0
0
Spain
Query!
State/province [39]
0
0
Santa Cruz de Tenerife
Query!
Country [40]
0
0
Spain
Query!
State/province [40]
0
0
Sevilla
Query!
Country [41]
0
0
United Kingdom
Query!
State/province [41]
0
0
Bradford
Query!
Country [42]
0
0
United Kingdom
Query!
State/province [42]
0
0
Manchester
Query!
Country [43]
0
0
United Kingdom
Query!
State/province [43]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Nektar Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is an open-label, randomized, active comparator, multicenter, international Phase 3
study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain
metastases and have been previously treated with an anthracycline, a taxane, and capecitabine
in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically
appropriate or contraindicated for the patient).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02915744
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02915744
Download to PDF